I

Iterative Health

AI-powered polyp detection for colorectal cancer

Sub Investigator - Nurse Practitioner

Full-Time
No salary listed
Mid
New Albany, IN, USA
In Person
Medical, Clinical & VeterinaryAdvanced Practice Providers

About the job

Requirements
  • Current unrestricted Nurse Practitioner license in the applicable state.
  • A minimum of three years of clinical research experience is strongly preferred.
  • The ability to own issues and solve problems independently.
  • The ability to read, interpret, and apply clinic policies and research protocols.
  • Proficiency in standard office software, electronic medical record systems, and electronic data capture platforms.
  • The ability to manage multiple priorities in a fast-paced, protocol-driven environment.
  • The ability to lift 25 pounds.
Responsibilities
  • Serve as a delegated Sub-Investigator on clinical research studies under the supervision of the Principal Investigator, as documented on the study Delegation of Authority Log.
  • Conduct comprehensive medical histories and protocol-required physical examinations, including screening, baseline, interim, and end-of-study assessments.
  • Evaluate potential study participants for eligibility based on protocol inclusion and exclusion criteria.
  • Conduct informed-consent discussions and obtain informed consent when delegated by the Principal Investigator and permitted by the protocol and applicable regulations.
  • Determine, in collaboration with the Principal Investigator, whether participants may continue study participation, require additional monitoring, or should be withdrawn for safety or protocol-related reasons.
  • Provide ongoing clinical care and medical oversight for research participants throughout study participation.
  • Assess, diagnose, and manage participant health concerns within the scope of licensure and delegated authority.
  • Monitor participant safety by evaluating adverse events, serious adverse events, abnormal test results, and concomitant medications, and escalate concerns to the Principal Investigator as appropriate.
  • Order, review, interpret, and sign protocol-required clinical assessments, laboratory reports, electrocardiograms, imaging studies, pathology reports, and procedure results as delegated by the Principal Investigator.
  • Prescribe study-related medications and other medically necessary treatments in accordance with study protocols, state law, and scope of practice.
  • Maintain accurate, complete, and timely clinical documentation in source records, electronic medical records, and electronic data capture systems.
  • Ensure protocol-required procedures, assessments, and visits are completed accurately and in accordance with sponsor requirements and Good Clinical Practice.
  • Review and complete medical documentation, source documentation, and study-related clinical assessments as delegated by the Principal Investigator.
  • Ensure compliance with Food and Drug Administration regulations, International Council for Harmonisation Good Clinical Practice guidelines, HIPAA, sponsor requirements, and applicable federal, state, and local regulations.
  • Maintain current licensure, national certification, DEA registration if applicable, required clinical research training, and continuing education.
  • Collaborate with Principal Investigators, clinical research coordinators, sponsors, monitors, and other research-team members to ensure successful study execution and participant safety.
  • Participate in protocol-feasibility assessments, site-initiation visits, monitoring visits, sponsor audits, and regulatory inspections.
  • Assist with implementing new clinical trials by reviewing protocols, identifying clinical requirements, and supporting study start-up activities.
  • Provide clinical guidance and mentorship to clinical research coordinators and other research staff regarding protocol requirements, participant safety, and study procedures.
  • Perform related duties.
Desired Qualifications
  • DEA registration or eligibility.
  • Cardiovascular clinical experience, or demonstrated willingness to develop expertise in the applicable therapeutic area.
  • Familiarity with Good Clinical Practice guidelines, Food and Drug Administration regulations, and International Council for Harmonisation standards governing clinical research.
  • Association of Clinical Research Professionals or Society of Clinical Research Associates certification, such as Certified Clinical Research Coordinator or Certified Clinical Research Professional, or active pursuit of certification.
  • Experience working within a multi-site clinical research network or sponsor-facing environment.
  • Strong written and verbal communication skills.
  • Highly organized.

About the company

Iterative Health develops and deploys AI-powered tools for gastrointestinal (GI) care. Its main product is SKOUT®, an FDA-cleared device that helps doctors find adenomas (polyps) during GI procedures, supporting clinical judgment rather than replacing it. The company also offers AI-enabled documentation and data standardization technologies to improve the quality of patient care and to streamline clinical trials, enabling consistent reporting across institutions. By combining AI image analysis, data-driven insights, and streamlined research workflows, Iterative Health aims to improve colorectal cancer prevention and diagnosis and to extend high-quality GI care to underserved populations around the world.

Company Size

201-500

Company Stage

Series C

Total Funding

$262.2M

Headquarters

Boston, Massachusetts

Founded

2017

Get referred to Iterative Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • April 30, 2026 Series C raised $77 million from GV and Intrepid Growth Partners.
  • July 2026 partnerships with GANJ and US Heart & Vascular widened patient access.
  • September 2026 leadership hires, including Dr. Nadege Gunn and Dr. Samin Sharma, sharpen credibility.

What critics are saying

  • Cardiology and obesity expansion now competes against entrenched site networks and academic centers.
  • SKOUT’s 510(k) clearance stays limited to colonoscopy, so product moat remains narrow.
  • If sponsor demand softens, Iterative’s labor-heavy site model strains margins and growth by 2027.

What makes Iterative Health unique

  • Iterative Health combines AI software, centralized operations, and embedded community research sites.
  • SKOUT has FDA clearance for real-time polyp detection during white-light colonoscopy only.
  • The network spans 110-plus sites across GI, hepatology, obesity, and cardiology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Vision/Dental/ Medical Insurance
  • Life/Disability Insurance
  • Parental Leave
  • Stock Options
  • Flexible Work Hours
  • Unlimited Paid Time Off

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

-5%
Associated Press
Aug 11th, 2026
Iterative Health appoints Mount Sinai's Dr Samin K. Sharma as honorary chair of interventional cardiology

Iterative Health has appointed Dr Samin K. Sharma as scientific advisor and honorary chair of interventional cardiology. Dr Sharma is director of the Cardiovascular Clinical Institute at Mount Sinai Hospital and director of interventional cardiology at Mount Sinai Health System. Dr Sharma has over 30 years of experience and has authored more than 350 peer-reviewed articles. He pioneered the use of the Rotablator technique for complex coronary blockages. The appointment follows Iterative Health's recent US site network expansion, including acquiring cardiology research sites from NextStage Clinical Research and partnering with US Heart & Vascular. The company's network spans more than 100 sites across three continents in GI, hepatology, obesity, and cardiology research.

Business Wire
Aug 11th, 2026
Iterative Health appoints Dr. Samin K. Sharma at Mount Sinai Hospital as honorary chair of Interventional Cardiology.

Iterative Health appoints Dr. Samin K. Sharma at Mount Sinai Hospital as honorary chair of Interventional Cardiology. CAMBRIDGE, Mass.-(BUSINESS WIRE)-Iterative Health, a healthcare technology and services company powering the acceleration of clinical research, today announced the appointment of Samin K. Sharma, MD, FACC, MSCAI, Director of the Cardiovascular Clinical Institute at The Mount Sinai Hospital, as a scientific advisor and honorary chair of Interventional Cardiology. In this role, Dr. Sharma brings best-in-class clinical and scientific leadership from one of the foremost academic medical centers to advance the company's cardiology strategy. "Dr. Sharma is a world-renowned physician recognized for his clinical judgment, commitment to patient-centered care, and contributions to the field," said Jonathan Ng, founder and CEO of Iterative Health. "His experience will help strengthen our therapeutic expertise, protocol and trial design, and scientific publications, ultimately helping our sites move studies forward with the excellence and rigor sponsors expect." Dr. Sharma is director of the S.P. and Seema Lohia Cardiovascular Clinical Institute and director of interventional cardiology at Mount Sinai Health System, where he also serves as president of the Mount Sinai Heart Network. With more than 30 years of experience, he is one of the most awarded cardiologists for his contributions to medical science. He is also credited with pioneering the use of the Rotablator technique for complex, calcified coronary blockages, has authored more than 350 peer-reviewed articles, and sits on the editorial boards of several cardiology journals. Dr. Sharma is passionate about medical education, mentoring fellows and experienced cardiologists alike through innovative teaching methods, including symposiums and live-broadcast cases that reach thousands. "There's a real gap between what a trial protocol asks for and what's actually workable at the bedside, and it can cost a study valuable time," said Dr. Sharma. "Iterative Health has built a research network around closing that gap, and it's an honor to help the company strengthen its impact in advancing cardiology research." The appointment follows Iterative Health's recent US site network expansion, including the acquisition of established cardiology research sites from NextStage Clinical Research and a strategic partnership with US Heart & Vascular. The company's network spans more than 100 high-performing sites across three continents in GI, hepatology, obesity, and cardiology research. About Iterative Health Iterative Health is a healthcare technology and services company powering the acceleration of clinical research to transform patient outcomes. By combining deep expertise in clinical trials with cutting-edge AI, we empower research teams and study sponsors to expand and expedite access to novel therapeutics for patients in need. The company has headquarters in Cambridge, Massachusetts, and New York, New York. For more information, visit www.iterative.health and follow us on LinkedIn for the latest company updates. Contacts. Media Contact Iterative Health: Andrea Sampson President/CEO, Sampson Public Relations Group [email protected] More News From Iterative Health CAMBRIDGE, Mass.-( BUSINESS WIRE )-Iterative Health and Gastroenterology Associates of New Jersey partnered to expand access to GI clinical research in New Jersey... CAMBRIDGE, Mass.-( BUSINESS WIRE )-Iterative Health announced the acquisition of three cardiology sites from NextStage Clinical Research... CAMBRIDGE, Mass.-( BUSINESS WIRE )-Iterative Health announced the presentation of updated scientific research at Digestive Disease Week (DDW) 2026...

Associated Press
Jul 8th, 2026
Iterative Health partners with GANJ to expand GI clinical research across New Jersey

Iterative Health has partnered with Gastroenterology Associates of New Jersey (GANJ) to expand clinical research access across New Jersey. The collaboration establishes two research sites in Toms River and Clifton, joining Iterative Health's network of over 110 sites globally. GANJ operates 28 locations across New Jersey with more than 60 healthcare professionals. The partnership integrates clinical research into community GI care, leveraging New Jersey's population of over 9.5 million residents and its ethnic diversity. Iterative Health will serve as GANJ's research partner, combining the practice's clinical expertise with its AI-powered technology and operational model. The collaboration focuses particularly on inflammatory bowel disease, with GANJ recently establishing a Comprehensive IBD Care Centre. Additional research sites are under discussion across GANJ's broader provider network. Iterative Health operates the largest community-embedded research site network in the US for GI, hepatology, obesity, and cardiology clinical development.

Planet First Partners
Jun 30th, 2026
Iterative Health raises $77M Series C to accelerate clinical trials with AI-powered research network

Planet First Partners has invested in Iterative Health, a healthcare technology company focused on accelerating clinical research. The investment follows Iterative Health's recent $77 million Series C funding round led by Intrepid Growth Partners and Google Ventures, with participation from EDBI, a family office, Insight Partners, and Obvious Ventures. Iterative Health operates a clinical research network spanning over 100 sites across North America, Europe, India, and Australia. The company uses AI and centralised operations to improve trial efficiency, achieving twice faster site activation and three times higher patient enrolment compared to industry standards. The Series C funds will support expansion into cardiology and obesity research, building on the company's existing focus on gastroenterology and hepatology. Iterative Health partners with over 40 pharmaceutical, biotech, and CRO organisations.

Business Wire
May 14th, 2026
Iterative Health acquires 3 cardiology sites from NextStage Clinical Research in Texas

Iterative Health, a healthcare technology and services company, has acquired three cardiology research sites in Texas from NextStage Clinical Research. The sites, located in Beaumont, Port Arthur and Waco, bring experienced research teams and established cardiovascular trial operations. The acquisition expands Iterative Health's cardiology footprint as part of its strategy to embed clinical research within community care settings. The company operates over 100 sites across three continents, supported by a 250-person team and proprietary AI tools for patient recruitment and trial design. Cardiovascular disease affects nearly half of US adults, yet clinical trial access remains uneven. The addition strengthens Iterative Health's capabilities across therapeutic areas including gastroenterology, hepatology and obesity, whilst providing patients access to innovative cardiovascular therapies and devices.